US 7,572,800 B2
	Combination therapy to treat hepatitis B virus
Phillip A. Furman, Durham, N.C. (US); George R. Painter, III, Chapel Hill, N.C. (US); David W. Barry, Chapel Hill, N.C. (US); and Franck Rousseau, Durham, N.C. (US)
Assigned to Gilead Sciences, Inc., Foster City, Calif. (US)
Filed on Feb. 25, 2003, as Appl. No. 10/374,363.
Application 10/374363 is a continuation of application No. 09/432247, filed on Nov. 02, 1999, granted, now 6,528,515, filed on Mar. 04, 2003.
Claims priority of provisional application 60/106664, filed on Nov. 02, 1998.
Prior Publication US 2003/0158150 A1, Aug. 21, 2003
Int. Cl. A61K 31/52 (2006.01); A61K 31/522 (2006.01)

U.S. Cl. 514—263.23  [514/263.1; 514/263.2; 514/263.3; 514/263.4]

4 Claims

1. A pharmaceutical composition for the treatment of hepatitis B virus in a human comprising an effective amount of β-2-hydroxymethyl-5-(5-fluorocytosin-1-yl) -1,3-oxathiolane (β-FTC) or a pharmaceutically acceptable salt or ester thereof in a combination with an effective amount of a second anti-hepatitis B agent selected from the group consisting of penciclovir wherein the amounts of β-FTC and penciclovir produce a synergistic anti-hepatitis B response.